1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Lack of evidence for infectious SARS-CoV-2 in feces and sewage

Sandra Albert¹, Alba Ruíz², Javier Pemán², Miguel Salavert ², Pilar Domingo-
Calap^{1,3*}

¹ Instituto de Biología Integrativa de Sistemas, Universitat de València-CSIC,
Paterna, Spain

² Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La
Fe, Valencia, Spain

³ Department of Genetics, Universitat de València, Burjassot, Spain

*corresponding author: Pilar Domingo-Calap, pilar.domingo@uv.es, +34 963
543 261, ORCID: 0000-0003-2829-8809

20 **Abstract**

21 **Purpose:** The SARS-CoV-2 coronavirus is a respiratory virus whose primary route of
22 transmission is airborne. However, it has been shown that the virus can replicate in
23 gastrointestinal cells, can be excreted in feces, and can reach sewage systems.
24 Although viral RNA has been found in patient feces and sewage, little is known about
25 the potential fecal-oral transmission of the coronavirus. Determining the presence of
26 infective viral particles in feces and sewage is necessary to take adequate control
27 measures and to discover new routes of coronavirus transmission.

28 **Methods:** Feces and urine of COVID-19 patients, and wastewater samples at the time
29 of high prevalence in the region under study (Valencia, Spain), have been analyzed
30 both by molecular methods and cell culture.

31 **Results:** Presence of SARS-CoV-2 in feces of COVID-19 patients has been detected,
32 even in patients without gastrointestinal symptoms, suggesting that viral shedding
33 though stool is common. In addition, we have developed a sample concentration
34 methodology that allows us to maintain the infectivity of the viral particles present in the
35 samples. Finally, inoculation of cell cultures with fecal and sewage concentrated
36 samples do not evidence the presence of infective viral particles.

37 **Conclusion:** There is no evidence of the presence of infectious SARS-CoV-2 in feces
38 and sewage, suggesting that fecal-oral transmission is not a primary route. However,
39 larger-scale efforts are needed to elucidate whether the fecal-oral transmission should
40 be considered, especially with the emergence of new viral variants.

41

42 **Keywords**

43 SARS-CoV-2; COVID-19, viral infectious particles; fecal-oral transmission

44

45 **Declarations**

46 **Funding**

47 This research was funded by FONDO-COVID19 COV20/00210 funded by
48 Instituto de Salud Carlos III to P.D-C. P.D-C. was supported by a Ramón y Cajal
49 contract from the Spanish Ministry of Science and Innovation, Call 2019.

50 **Conflicts of interest**

51 The authors have no conflicts of interest to declare.

52 **Availability of data and material**

53 The data that support the findings of this study are available from the
54 corresponding author, upon reasonable request.

55 **Code availability**

56 Not applicable.

57 **Ethics approval**

58 This study has been approved by the ethics committee of the Instituto de
59 Investigación Sanitaria La Fe (Valencia, Spain).

60 **Consent to participate**

61 Informed consent was obtained from all individual participants included in the
62 study.

63 **Consent for publication**

64 The authors declare consent for publication.

65 Introduction

66 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
 67 pandemic affecting the entire world. Although the main transmission route is via
 68 droplets or aerosols [1], it has been shown that the virus can replicate in intestinal
 69 mucosa [2], suggesting that viral excretion via feces could result in fecal-oral
 70 transmission of SARS-CoV-2 [3, 4]. Despite the efforts to isolate viral infectious
 71 particles from feces, little is known about the possibility of infecting new hosts via feces.
 72 In a first approach, it is necessary to determine the proportion of patients excreting
 73 virus in stool by analyzing fecal samples and testing them by molecular methods to
 74 detect viral RNA. In a second step, positive samples should be used to inoculate target
 75 cells expressing angiotensin-converting enzyme 2 (ACE2), the main receptor for
 76 SARS-CoV-2 [5], to determine the presence of infectious viruses in stool. Viral
 77 shedding in stool has been suggested to be more prolonged than in the respiratory
 78 tract, up to 5 weeks after respiratory samples have tested negative for SARS-CoV-2
 79 RNA, even in mild or non-symptomatic patients [6, 7], including children [8].

80 The presence of SARS-CoV-2 RNA in feces has interesting applications, such
 81 as the implementation of new detection techniques through anal swabs (Sun et al.
 82 2020), or epidemiological surveillance of SARS-CoV-2 through wastewater [10].
 83 However, further efforts should be made to determine the proportion of patients
 84 shedding virus through feces, viral load per individual, and other parameters in order to
 85 use this specimen as a monitoring tool to correlate with incidence in the population.
 86 Therefore, it is important to determine whether positive specimens contain infectious
 87 particles, as only a few case reports have shown that viral infectious particles are found
 88 in stool [11–13]. Recently, fecal-oral transmission has been proposed as the most
 89 plausible explanation for two independent outbreaks in China, suggesting viral spread
 90 via sewage aerosols in a building [14], and via sewage in a residential home [15]. In
 91 both cases, SARS-CoV-2 RNA sequencing supported the hypotheses. However,

92 further efforts should be done to assess the fecal-oral route in SARS-CoV-2, and
93 provide data based on the presence of infectious viral particles confirming the new
94 route of transmission [12].

95 Here we propose the first attempt to evaluate the fecal excretion of SARS-CoV-
96 2 in Spain, and the presence of viral infectious particles in feces, in a single-center
97 study based on a small cohort of COVID-19 patients. In addition, to determine the
98 possibility of the fecal-oral route, SARS-CoV-2 positive wastewater samples from
99 Wastewater Treatment Plants of Valencia (Spain) were used to study the presence of
100 viral particles.

101 **Materials and Methods**

102 *Human subjects*

103 This study has been approved by the ethics committee of the Instituto de
104 Investigación Sanitaria La Fe (Valencia, Spain) to use patient samples, including urine
105 and feces. In total, eight mild-symptomatic patients admitted to the Hospital Universitari
106 y Politècnic La Fe between June and December 2020 we enrolled in this study.
107 Informed consent was obtained from each patient. The criterion for inclusion in the
108 study was to be over 18 years of age. Diagnosis and data collection from medical
109 records were used. RT-qPCR on nasopharyngeal swabs was performed at the hospital
110 following internal guidelines using different commercial available kits (BioFire®
111 Respiratory Panel 2.1 (BioFire Defense LLC and BioFire Diagnostics LLC), Alinity m
112 SARS-CoV-2 assay (Abbott Molecular), and Simplexa™ COVID-19 Direct (DiaSorin
113 Molecular LLC)). Unfortunately, we were not able to recover the Ct values from
114 nasopharyngeal swabs. Stool and urine samples were both suspended in Sigma
115 Virocult viral transport medium without viral inactivators (W951S, MWE medical wire)
116 and kept at 4°C until laboratory handling within 24 hours.

117 *Sewage samples*

118 Wastewater from the metropolitan Wastewater Treatment Plants of Valencia
119 (Spain) belonging to the Empresa Pública de Saneamiento de Aguas Residuales
120 (EPSAR, Generalitat Valenciana) was sampled from December 2020 to January 2021.
121 Grab and four-hour composite samples of 200 mL of sewage were collected in the
122 morning. Samples were kept at 4 °C until they were processed in the laboratory within
123 24h of collection.

124 *Sewage sample concentration*

125 Sewage samples were treated to allow viral particle concentration. Three
126 different methods were tested: flocculation, ultra-filtration, and high-speed
127 centrifugation. As a first common step, 10^5 particle forming units (PFU) of the
128 transmissible gastroenteritis virus (TGEV) were added to the wastewater samples as a
129 surrogate virus. This was followed by gentle centrifugation at $3,000 \times g$, 10 min, at 4°C,
130 and the supernatant was filtered through a 0.45 µm pore. Aluminum-driven flocculation
131 was done in 50 mL of sewage, adjusting to pH 6.0, and adding 1:100 v:v of 0.9 N $AlCl_3$
132 solution. $Al(OH)_3$ precipitate was formed and after pH readjustment to 6.0, samples
133 were gently agitated for 15 min at room temperature, and spun at $1,700 \times g$ for 20 min.
134 Pellets were resuspended into 10 mL of 3% beef extract (pH 7.4), and shaken for 10
135 min at 150 rpm. Samples were then centrifuged at $1,900 \times g$ for 30 min and the pellet
136 was resuspended in 1 mL of phosphate buffer (PBS) (Randazzo et al., 2020). Ultra-
137 filtration method was done in 20 mL of sewage. Amicon tubes with 100KDa filters were
138 used, and after $3,200 \times g$, 30 min, at 4°C, the residual liquid in the upper part of the
139 filter was collected. High-speed centrifugation method was done in 35 mL of filtered
140 wastewater, centrifuged at $80,000 \times g$, 3 h 30 min, at 4°C. The supernatant was
141 removed and the pellet was resuspended in 500 µL of PBS.

142 *Processing of fecal samples*

143 Fecal samples were resuspended in PBS to a final volume of 2 mL. Samples
144 were then centrifuged at 3220 × g, 10 min, at 4°C twice to recover viruses in the
145 supernatant. The supernatants were filtered through a 0.45 µm pore.

146 *RNA extraction and RT-qPCR*

147 RNA extraction was performed with the Nucleospin RNA Virus Kit (Macherey-
148 Nagel) following the recommended protocols. RT-qPCR was performed with the
149 GoTaq® Probe 1-Step RT-qPCR System (Promega) using the U.S. Center for Disease
150 Control N1 and N2 primers sets (2019-nCoV CDC EUA Kit, 1000rxn) provided by IDT
151 (Integrated DNA Technologies). For each RT-qPCR run, calibration curves were
152 performed using the 2019-nCoV_N_Positive Control provided by IDT. In addition,
153 positive and negative controls (concentration, extraction and PCR) were included. To
154 estimate viral loads, cycle threshold (Ct) values were used to calculate genomic copies
155 (gc) per liter in the original sample due to calibration curves. Ct values bellow 40 were
156 considered positive for SARS-CoV-2, as previously proposed [16]. All the experiments
157 were performed in duplicate. In addition, and as an internal control, in-house TGEV
158 primers were used to evaluate the efficacy of the protocol.

159 *High-throughput sequencing*

160 Genomic sequencing was performed following the protocol of retrotranscription
161 and amplification of ARTIC, using the amplification protocol, using the V3 version
162 scheme for multiplex PCRs. This was followed by the preparation of libraries using the
163 Nexus kit using the Nextera Flex kit (Illumina) and their sequencing on the Illumina
164 MiSeq platform (paired-end reads 2x200 bp) [17].

165 *Cell culture*

166 Fecal specimens and sewage samples with highest RNA detected by RT-qPCR
167 were used to inoculate Vero E6 cells. To maintain infectivity, the high-speed

168 centrifugation method was used to concentrate viruses in positive samples, as
169 previously tested with TGEV.

170 Sewage samples were centrifuged at 3000 × g, 10 min, at 4°C and the
171 supernatant was filtered through a 0.45 µm pore. Thirty-five mL of filtrate was
172 centrifuged at 80,000 × g, 3h 30min, at 4°C and the pellet was resuspended in 500 µL
173 of Dulbecco Modified Eagle Medium (DMEM) supplemented with 2% fetal bovine
174 serum, non-essential amino acids, penicillin and streptomycin.

175 Fecal samples were centrifuged 3h 30min at 20,000 × g at 4°C to recover
176 viruses, which were resuspended in 400 µL of Dulbecco Modified Eagle Medium
177 (DMEM) supplemented with 2% fetal bovine serum, non-essential amino acids,
178 penicillin and streptomycin, and 25 mM Hepes. All samples were analyzed undiluted
179 and at 1/10 dilution. Diluted samples were used to avoid potential sample inhibitors or
180 cytotoxic molecules. Negative controls were added in all experiments. For sewage, a
181 negative RT-qPCR sample sampled in July 2020 was used as a negative control. For
182 feces, a canine fecal sample was used as a negative control. Vero E6 cells were
183 inoculated at 70% confluence with diluted and undiluted fecal or wastewater samples.
184 Cultures were incubated at 37°C and 5% CO₂ for six dpi. Replication of SARS-CoV-2 in
185 cells cultures was analyzed by RT-qPCR, at 0 hpi, 48 hpi and 6 dpi. 100 µL of the
186 supernatant was recovered and treated with DNA/RNA Shield (Zymo Research) for
187 each time point to inactivate the viruses and proceed to RNA extraction and RT-qPCR
188 as explained above. In addition, microscopy images were taken to detect cytopathic
189 effects of cell monolayers. All the experiments were performed in triplicate.

190 **Results**

191 ***Patients***

192 This study was performed on a cohort of eight COVID-19 patients admitted to
193 the Hospital Universitari i Politècnic La Fe (Valencia, Spain) between June and

December 2020. In our cohort, 5 patients of the 8 showed respiratory symptoms, and only 3 had gastrointestinal (GI) symptoms. Other common symptoms, such as fever and headache, were very frequent in patients. None of the patients included in our cohort were admitted to intensive care units. Fecal and urine samples were collected from the patients to determine the presence of SARS-CoV-2, and in some of them we had access to longitudinal samples (Table 1).

Sample concentration comparison

Different sample concentration methods were tested to select a protocol capable of concentrating the virus while maintaining viral infectivity, using the transmissible gastroenteritis coronavirus (TGEV) as model. The three methods tested were: ultrafiltration, aluminum-driven flocculation, and high-speed centrifugation. The concentration factor was obtained by RTqPCR using in-house primers and probes, and by plaque assay infecting swine testicular (ST) cells. Six replicates were performed per method. For maintaining infectivity, high-speed centrifugation was the best method (concentration factor: 31.29 ± 6.49), followed by ultrafiltration (concentration factor: 7.38 ± 1.26). In contrast, infectivity was impaired by aluminum-driven flocculation (concentration factor: 0.02 ± 0.02). As for RNA detection, high-speed centrifugation obtained similar results to the aluminum-driven flocculation method (concentration factor: 14.98 ± 0.91 vs. 16.42 ± 2.13), whereas ultrafiltration was not suitable (concentration factor: 2.85 ± 0.87). For these reasons, the high-speed centrifugation method was chosen as the best in terms of concentration and maintenance of viral infectivity.

Detection of SARS-CoV-2 RNA in fecal and urine samples

The presence of SARS-CoV-2 in the patient samples was evaluated by RT-qPCR in urine and feces. Internal controls using the surrogate TGEV coronavirus were used in all the samples, validating the efficacy of our protocol (data not shown). The

220 results showed that 6 of the 8 patients had viral excretion in feces in at least one of the
221 samples analyzed, ranging from 8.34×10^3 gc/L to 6.74×10^6 gc/L (Table 2). One of
222 the negative patients, it is worth mentioning that he was negative despite suffering from
223 GI symptoms. The absence of viral shedding in this patient was not expected, and a
224 possible explanation is that the sample was taken one month after the onset of the first
225 symptoms, suggesting that perhaps earlier sampling might have different results. In
226 parallel, urine samples were collected for patients to test for RNA detection. In our
227 dataset, one patient showed viral shedding in urine in two consecutive samples,
228 despite the low viral load found (ranging from 5.60×10^4 gc/L to 1.78×10^5 gc/L).

229 ***SARS-CoV-2 sequencing attempt in fecal samples***

230 In addition, we wanted to sequence the RNA obtained in the feces to analyze
231 the variability found in stool. Unfortunately, the viral loads obtained in the feces of the
232 patients tested were too low for viral sequencing. Despite the low copy number per mL
233 in our samples, we attempted to sequence the sample with highest viral load, but the
234 results were insufficient for further analysis. Using the Illumina MiSeq sequencer, and
235 following the ARTICV3 + Nextera Flex protocol, only 13.28% of the SARS-CoV-2
236 genome was covered, with a coverage of 2 (unpublished data). Our results are
237 consistent with previous data in which samples with low viral load are difficult to
238 sequence [18]. Since the Ct values of the other samples were higher than those of the
239 tested sample, we decided not to continue with the sequencing protocol for the
240 remaining samples.

241 ***Potential contribution of fecal shedding to SARS-CoV-2 transmission***

242 To determine whether RNA found in feces was capable of infecting new hosts,
243 we attempted to determine by cell culture the presence of infectious SARS-CoV-2
244 particles in positive samples, using 8 samples from 5 patients. Vero E6 cells were
245 used as recommended cell models for SARS-CoV-2 infection [19]. Isolation of viral

246 particles from feces and inoculation of cell monolayers were performed. Three
247 sampling points were analyzed, 0 hours post-infection (hpi), 48 hpi and 6 days post-
248 infection (dpi). No cytopathic effect on Vero E6 cells was observed in any of the
249 samples analyzed (Figure 1). However, supernatants were collected and RT-qPCR
250 was performed to detect viral amplification. In all samples tested no SARS-CoV-2 RNA
251 was detected, suggesting the absence of viral particles in the cultures tested, despite
252 the RNA found in the fecal samples (Table 3).

253 ***Potential contribution of wastewater to SARS-CoV-2 transmission***

254 Further, we wanted to determine the potential contribution of wastewater to
255 SARS-CoV-2 transmission. Eight sewage samples from wastewater treatment plants in
256 Valencia (Spain) between December 2020 and January 2021, where the incidence rate
257 in the target population was higher than 1000 per 100000 people. Samples were
258 concentrated by high-speed centrifugation to ensure virus viability and analyzed by RT-
259 qPCR and cell culture. Again, despite the high viral load obtained in the samples
260 (ranging from 1.43×10^4 gc/L to 1.48×10^6 gc/L) (Table 4), we were unable to detect
261 evidence of replication in our assays (Table 5).

262 **Discussion**

263 Fecal shedding of SARS-CoV-2 has been reported in patients with COVID-19
264 and in asymptomatic infected individuals. However, the possible fecal-oral transmission
265 route of the coronavirus is still under discussion. Our results are in agreement with
266 those previously published on the detection of SARS-CoV-2 in the stool of COVID-19
267 patients [20]. However, we were able to detect viral RNA in stool in 6/8 patients, being
268 a high percentage compared to previously published results, and suggesting that the
269 virus may be detected more frequently in stool than expected based on previously
270 published results [21]. Furthermore, our results suggest that GI symptoms and the
271 presence of SARS-CoV-2 in feces are not correlated, as only 3 patients had GI

272 symptoms. This result could have implications for the use of anal swabs as recently
273 suggested. However, the implementation of more sensitive detection methods
274 associated with fecal samples could be an interesting solution to develop non-invasive
275 easy-to-use, rapid tests, than can be performed by common users, avoiding
276 nasopharyngeal swabs, since nasal self-swabbing can lead to inadequate sample
277 collection resulting in false negative conclusions. Thus, the results obtained in this
278 study, despite the low number of patients included, suggest that the presence of
279 SARS-CoV-2 in feces is common, and support the use of anal testing for its detection.

280 To unravel the fecal-oral route of SARS-CoV-2 transmission, fecal samples
281 have been analyzed in cell culture for the presence of infectious viral particles. The lack
282 of evidence of infectivity in fecal samples could be due to the low viral load found in our
283 samples, with high Ct values, in contrast with previously published results in which
284 infectious coronavirus was found in a sample with a Ct value ranging 20-23 [11]. The
285 fact that only a few cases of infectious particles in feces have been reported so far
286 suggests that although transmission through feces might exists, it should not be
287 considered as a major route. To go further, sewage samples at the time of highest
288 incidence in Valencia (Spain) were tested in cell culture. Despite the high viral load
289 found in wastewater, no viral replication was detected in the samples tested,
290 suggesting that transmission of SARS-CoV-2 through stool or sewage should be minor
291 or absent. In agreement with our results, a recent study in China was unable to detect
292 viable virus in hospital wastewater [22].

293 We strongly suggest increased effort to continue testing more patients,
294 including asymptomatic patients, to get a broader view of viral shedding in feces.
295 Further evidence should be conducted in a single-center study involving a large cohort
296 to draw supported conclusions. In addition, sewage sampled directly from sewers could
297 be an interesting approach to detect possible infectious particles, avoiding the
298 wastewater treatment plants, where viral particles could be inactivated due to external

299 factors such as temperature, humidity, or chemical agents in the matrix, which may
300 remove or impact the envelope.

301 Finally, we used RT-qPCR for RNA detection following the CDC
302 recommendations, and the recommended cellular model for SARS-CoV-2 infection.
303 However, improved detection methodologies using more sensitive and efficient
304 techniques, both in molecular diagnostic and cell culture, could lead to different results.
305 Therefore, further characterization of fecal and sewage samples is mandatory to
306 unravel the possible fecal-oral route of SARS-CoV-2 transmission, and will be an
307 interesting topic for future research, especially with the emergence of new viral
308 variants.

309 **Acknowledgements**

310 We thank to M. Carmen Montaner from the Hospital Universitari i Politècnic La
311 Fe for her support in the collection of the samples. We thank the Generalitat
312 Valenciana and the Empresa Pública de Saneamiento de Aguas Residuales (EPSAR)
313 for providing access to wastewater. We also want thank Dr. Antonio Alcamí for the
314 Vero E6 cells. This research was funded by FONDO-COVID19 COV20/00210 funded
315 by Instituto de Salud Carlos III to P.D-C. P.D-C. was supported by a Ramón y Cajal
316 contract from the Spanish Ministry of Science and Innovation, Call 2019.

317

318 **References**

- 319 1. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ (2020) Identifying airborne
320 transmission as the dominant route for the spread of COVID-19. PNAS
321 117:14857–14863. <https://doi.org/10.1073/pnas.2009637117>
- 322 2. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020) Evidence for
323 Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 158:1831–1833.
324 <https://doi.org/10.1053/j.gastro.2020.02.055>
- 325 3. Jones DL, Baluja MQ, Graham DW, Corbishley A, McDonald JE, Malham SK,
326 Hillary LS, Connor TR, Gaze WH, Moura IB, Wilcox MH, Farkas K (2020)
327 Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-

- 328 person transmission and the environment-based spread of COVID-19. *Sci Total*
329 *Environ* 749:141364. <https://doi.org/10.1016/j.scitotenv.2020.141364>
- 330 4. Guo M, Tao W, Flavell RA, Zhu S (2021) Potential intestinal infection and faecal–
331 oral transmission of SARS-CoV-2. *Nat Rev Gastroenterol Hepatol* 18:269–238.
332 <https://doi.org/10.1038/s41575-021-00416-6>
- 333 5. Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G,
334 Bianco A (2020) ACE2: The Major Cell Entry Receptor for SARS-CoV-2. *Lung*
335 198:867–877. <https://doi.org/10.1007/s00408-020-00408-4>
- 336 6. Mesoraca A, Margiotti K, Viola A, Cima A, Sparacino D, Giorlandino C (2020)
337 Evaluation of SARS-CoV-2 viral RNA in fecal samples. *Virol J* 17:86.
338 <https://doi.org/10.1186/s12985-020-01359-1>
- 339 7. Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, Yin H, Xiao Q, Tang Y, Qu X,
340 Kuang L, Fang X, Mishra N, Lu J, Shan H, Jiang G, Huang X (2020) Prolonged
341 presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol*
342 *Hepatol* 5:434–435. [https://doi.org/10.1016/S2468-1253\(20\)30083-2](https://doi.org/10.1016/S2468-1253(20)30083-2)
- 343 8. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J,
344 Zhang H, Liu H, Xia H, Tang J, Zhang K, Gong S (2020) Characteristics of
345 pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral
346 shedding. *Nat Med* 26:502–505. <https://doi.org/10.1038/s41591-020-0817-4>
- 347 9. Sun M, Guo D, Zhang J, Zhang J, Teng H-F, Xia J, Liu P, Ge Q-X, Wang M-Y
348 Anal swab as the potentially optimal specimen for SARS-CoV-2 detection to
349 evaluate the hospital discharge of COVID-19 patients. *Future Microbiol* 15:1101–
350 1107. <https://doi.org/10.2217/fmb-2020-0090>
- 351 10. Hamouda M, Mustafa F, Maraqa M, Rizvi T, Aly Hassan A (2021) Wastewater
352 surveillance for SARS-CoV-2: Lessons learnt from recent studies to define future
353 applications. *Sci Total Environ* 759:143493.
354 <https://doi.org/10.1016/j.scitotenv.2020.143493>
- 355 11. Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, Zhao J, Huang J, Zhao J (2020)
356 Infectious SARS-CoV-2 in feces of patient with severe COVID-19. *Emerg Infect*
357 *Dis* 26:1920-1922. <https://doi.org/10.3201/eid2608.200681>
- 358 12. Cuicchi D, Lazzarotto T, Poggioli G (2020) Fecal-oral transmission of SARS-CoV-
359 2: review of laboratory-confirmed virus in gastrointestinal system. *Int J Colorectal*
360 *Dis* 36:437–444. <https://doi.org/10.1007/s00384-020-03785-7>
- 361 13. Jeong HW, Kim S-M, Kim H-S, Kim Y-I, Kim JH, Cho JY, Kim S, Kang H, Kim S-
362 G, Park S-J, Kim E-H, Choi YK (2020) Viable SARS-CoV-2 in various specimens
363 from COVID-19 patients. *Clin Microbiol Infect* 26:1520–1524.
364 <https://doi.org/10.1016/j.cmi.2020.07.020>
- 365 14. Kang M, Wei J, Yuan J, Guo J, Zhang Y, Hang J, Qu Y, Qian H, Zhuang Y, Chen
366 X, Peng X, Shi T, Wang J, Wu J, Song T, He J, Li Y, Zhong N (2020) Probable
367 Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building.
368 *Ann Intern Med* 173:974–980. <https://doi.org/10.7326/M20-0928>
- 369 15. Yuan J, Chen Z, Gong C, Liu H, Li B, Li K, Chen X, Xu C, Jing Q, Liu G, Qin P,
370 Liu Y, Zhong Y, Huang L, Zhu B-P, Yang Z (2020) Sewage as a Possible

- 371 Transmission Vehicle During a Coronavirus Disease 2019 Outbreak in a Densely
372 populated Community: Guangzhou, China, April 2020. Clin Infect Dis ciaa1494 .
373 <https://doi.org/10.1093/cid/ciaa1494>
- 374 16. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (2020) Detection of SARS-
375 CoV-2 in Different Types of Clinical Specimens. JAMA 323:1843–1844.
376 <https://doi.org/10.1001/jama.2020.3786>
- 377 17. Quick J (2020) nCoV-2019 sequencing protocol.
378 <https://doi.org/10.17504/protocols.io.bbmuk6w>
- 379 18. Meredith LW, Hamilton WL, Warne B, Houldcroft CJ, Hosmillo M, Jahun AS,
380 Curran MD, Parmar S, Caller LG, Caddy SL, Khokhar FA, Yakovleva A, Hall G,
381 Feltwell T, Forrest S, Sridhar S, Weekes MP, Baker S, Brown N, Moore E, Popay
382 A, Roddick I, Reacher M, Gouliouris T, Peacock SJ, Dougan G, Török ME,
383 Goodfellow I (2020) Rapid implementation of SARS-CoV-2 sequencing to
384 investigate cases of health-care associated COVID-19: a prospective genomic
385 surveillance study. Lancet Infect Dis 20:1263–1271.
386 [https://doi.org/10.1016/S1473-3099\(20\)30562-4](https://doi.org/10.1016/S1473-3099(20)30562-4)
- 387 19. Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer
388 Y, Caly L, Druce J, de Vries JJC, Kikkert M, Bárcena M, Sidorov I, Snijder EJ
389 (2020) SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid
390 adaptation and cytopathology. J Gen Virol 101:925–940.
391 <https://doi.org/10.1099/jgv.0.001453>
- 392 20. Amirian ES (2020) Potential fecal transmission of SARS-CoV-2: Current evidence
393 and implications for public health. Int J Infect Dis 95:363–370.
394 <https://doi.org/10.1016/j.ijid.2020.04.057>
- 395 21. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, Ng YY, Chu MY,
396 Chung TWH, Tam AR, Yip CCY, Leung K-H, Fung AY-F, Zhang RR, Lin Y, Cheng
397 HM, Zhang AJX, To KKW, Chan K-H, Yuen K-Y, Leung WK (2020)
398 Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal
399 samples from a Hong Kong cohort: systematic review and meta-analysis.
400 Gastroenterol 159:81–95. <https://doi.org/10.1053/j.gastro.2020.03.065>
- 401 22. Wang J, Feng H, Zhang S, Ni Z, Ni L, Chen Y, Zhuo L, Zhong Z, Qu T (2020)
402 SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during
403 the Coronavirus Disease 2019 outbreak in a Chinese hospital. Int J Infect Dis
404 94:103–106. <https://doi.org/10.1016/j.ijid.2020.04.024>

405

406

407 **Figure**

408

409

410

411 **Figure 1. Representative images of Vero E6 cultures obtained at different time**
412 **points inoculated with fecal-treated samples.** Undiluted and 1/10 diluted samples
413 were tested for each sample. Magnification: 40X. In patient 1, 1/7 and 2/7 refer to two
414 different samples.

415 Tables

416

417 **Table 1. Main characteristics of the COVID-19 cohort included in the study.** PCR
418 + nasopharyngeal swab to validate SARS-CoV-2 infection. GI: gastrointestinal.

419

Patient code	Gender	Admission date	Fever	Headache	Odinophagy	Respiratory symptoms	Anosmia	Dysgeusia	GI symptoms
1	Male	Jun 2020	NO	YES	YES	NO	NO	NO	NO
2	Male	Jun 2020	YES	YES	NO	NO	NO	NO	NO
3	Male	Jun 2020	YES	YES	NO	NO	NO	NO	NO
4	Male	Jun 2020	YES	YES	NO	YES	NO	NO	NO
5	Female	Jul 2020	YES	YES	YES	YES	NO	NO	YES
6	Male	Sep 2020	YES	YES	NO	YES	NO	NO	YES
7	Male	Nov 2020	YES	YES	NO	YES	NO	NO	NO
8	Male	Dec 2020	NO	YES	YES	YES	NO	NO	YES

420

421

422 **Table 2. Detection of SARS-CoV-2 RNA in feces and urine of COVID-19 patients**
 423 **by RT-qPCR.**

424

Patient code	Sampling date	Specimen	Ct N1	gc/L N1*	Ct N2	gc/L N2*	Cell culture test
1	Jun 2020	Feces	ND ND	ND	ND ND	ND	No
		Urine	ND ND	ND ND	ND 43.000	0	
	Jul 2020	Feces	36.664 36.479	1.13×10^6	ND ND	ND	Yes
		Urine	ND ND	ND	ND ND	ND	
	Jul 2020	Feces	34.304 34.137	1.60×10^6	38.266 36.346	1.53×10^6	Yes
		Urine	ND ND	ND	ND ND	ND	
2	Jul 2020	Feces	ND 37.006	9.43×10^4	41.295 41.281	0	Yes
		Urine	ND ND	ND	42.442 ND	0	
	Jul 2020	Urine	ND ND	ND	ND ND	ND	No
3	Jul 2020	Feces	35.130 33.152	2.20×10^6	36.122 35.675	3.43×10^6	Yes
		Urine	ND ND	ND	ND ND	ND	
	Jul 2020	Feces	ND ND	ND	ND ND	ND	No
		Urine	ND ND	ND	43 ND	0	
4	Jul 2020	Feces	31.826 33.183	6.74×10^6	35.159 35.049	6.00×10^6	Yes
		Urine	ND ND	ND	ND ND	ND	
	Jul 2020	Feces	ND ND	ND	ND ND	ND	No
		Urine	ND ND	ND	ND ND	ND	
5	Jul 2020	Urine	ND ND	ND	ND ND	ND	No
6	Sep 2020	Feces	38.334 37.578	5.04×10^4	39.869 ND	4.49×10^4	Yes
		Urine	ND ND	ND	ND 38.980	1.78×10^5	
	Sep 2020	Feces	ND 38.967	8.34×10^3	39.005 39.750	9.88×10^4	Yes

		Urine	37.887 ND	5.60×10^4	40.458 ND	0	
	Sep 2020	Feces	ND ND	ND	40.421 40.739	0	Yes
		Urine	ND 37.534	7.46×10^4	ND 39.332	1.38×10^5	
7	Nov 2020	Feces	38.599 ND	1.21×10^6	ND ND	ND	No
8	Jan 2021	Feces	ND ND	ND	42.730 ND	0	No

425 *average gc/L per sample

426 ND: non detected

427

428 **Table 3. Detection of SARS-CoV-2 RNA in inoculated Vero E6 cultures with**
 429 **treated feces of COVID-19 patients by RT-qPCR after 0 hpi, 48 hpi and 6 dpi.**

430

Patient code	Sampling date	Dilution	0 hpi			48 hpi			6 dpi					
			Ct N1	gc/L N1*	Ct N2	gc/L N2*	Ct N1	gc/L N1*	Ct N2	gc/L N2*	Ct N1	gc/L N1*	Ct N2	gc/L N2*
1	Jul 2020	1/10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	Jul 2020	Undiluted	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
2	Jul 2020	1/10	ND	ND	ND	ND	38.151	0	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	0	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	0	ND	ND	ND	ND	ND	ND
	Jul 2020	Undiluted	ND	ND	ND	ND	ND	40.586	0	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	41.534	0	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	41.117	0	ND	ND	ND	ND	ND
3	Jul 2020	1/10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	Jul 2020	Undiluted	ND	ND	ND	ND	37.936	0	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	0	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
4	Jul 2020	1/10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	Jul 2020	Undiluted	38.721	0	ND	ND	ND	0	ND	ND	ND	ND	ND	ND
			39.059	0	ND	ND	37.993	0	ND	ND	ND	ND	ND	ND
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
6	Sep 2020	1/10	ND	ND	ND	ND	ND	ND	41.001	0	-	-	-	-
			ND	ND	ND	ND	ND	ND	ND	ND	-	-	-	-
			ND	ND	ND	ND	ND	ND	ND	ND	-	-	-	-
	Sep 2020	Undiluted	37.815	0	ND	ND	ND	ND	ND	ND	-	-	-	-
			ND	ND	ND	ND	ND	ND	ND	ND	-	-	-	-
			ND	ND	ND	ND	ND	ND	ND	ND	-	-	-	-
	Sep 2020	1/10	ND	ND	ND	ND	38.313	0	ND	ND	-	-	-	-
			ND	ND	ND	ND	ND	ND	ND	ND	-	-	-	-
			ND	ND	ND	ND	ND	ND	ND	ND	-	-	-	-
	Sep 2020	Undiluted	ND	ND	44.827	0	ND	ND	40.613	0	-	-	-	-
			ND	ND	41.165	0	ND	ND	ND	0	-	-	-	-
			37.959	0	41.22	0	ND	ND	40.831	0	-	-	-	-

431 * average gc/L per sample

432 ND: non detected

433

434

435

436

437 **Table 4. Detection of SARS-CoV-2 RNA in wastewater by RT-qPCR.**

WWTP	Sampling date	Ct N1	gc/L N1 [*]	Ct N2	gc/L N2 [*]
Pinedo 2	29 Jul 2020	30.251 29.993	7.31×10^5	32.882 32.763	9.91×10^5
Pinedo 2	3 Aug 2020	29.570 29.687	1.27×10^6	31.675 31.381	1.48×10^6
Pinedo 1	3 Aug 2020	31.507 31.671	3.75×10^5	33.602 33.445	3.93×10^5
Pinedo 2	4 Aug 2020	32.410 32.460	2.05×10^5	34.798 34.305	1.97×10^5
Pinedo 1	5 Aug 2020	32.781 32.880	1.17×10^5	35.112 35.018	7.04×10^4
Pinedo 1	17 Aug 2020	31.833 31.631	2.80×10^4	32.384 ND	1.43×10^4
Pinedo 1	8 Nov 2020	34.380 34.165	1.45×10^5	37.177 40.124	4.81×10^4
Pinedo 2	8 Nov 2020	34.122 34.822	1.30×10^5	37.803 38.378	5.54×10^4

438 ^{*} average gc/L per sample

439 ND: non detected

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460 **Table 5. Detection of SARS-CoV-2 RNA in inoculated Vero E6 cultures with**
 461 **concentrated wastewater by RT-qPCR after 0 hpi, 48 hpi and 6 dpi.**

462

			0 hpi				48 hpi				6 dpi				
WWTP	Sampling date	Dilution	Ct N1	gc/L N1*	Ct N2	gc/L N2*	Ct N1	gc/L N1*	Ct N2	gc/L N2*	Ct N1	gc/L N1*	Ct N2	gc/L N2*	
Pinedo 2	29 Jul 2020	1/10	ND	ND	42.162	0	ND	ND	40.814	0	ND	ND	ND	ND	
			ND	ND	ND	0	ND	ND	ND	ND	ND	ND			
		Undiluted	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Pinedo 2	3 Aug 2020	1/10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
		Undiluted	ND	ND	40.609	0	ND	ND	ND	ND	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Pinedo 1	3 Aug 2020	1/10	ND	ND	43.000	0	39.885	0	ND	ND	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
		Undiluted	ND	ND	ND	ND	ND	ND	41.148	0	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Pinedo 2	4 Aug 2020	1/10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
		Undiluted	ND	ND	ND	ND	ND	ND	42.262	0	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	0	ND	ND	ND	ND	
Pinedo 1	5 Aug 2020	1/10	ND	ND	ND	ND	ND	ND	41.77	0	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	41.268	0	ND	ND	ND	ND	
		Undiluted	ND	ND	42.502	0	ND	ND	42.508	0	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Pinedo 1	17 Aug 2020	1/10	ND	0	ND	ND	38.150	0	ND	ND	ND	ND	ND	ND	
			40.858	ND	ND	ND	38.137	ND	ND	ND	ND	ND	ND	ND	
		Undiluted	39.047	0	ND	0	ND	ND	43.976	0	ND	ND	ND	ND	
			ND	ND	41.307	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Pinedo 1	8 Nov 2020	1/10	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
		Undiluted	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	39.732	0
			ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
Pinedo 2	8 Nov 2020	1/10	ND	0	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
			37.472	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
		Undiluted	ND	ND	ND	ND	ND	ND	ND	ND	38.861	0	ND	0	
			ND	ND	ND	ND	ND	ND	ND	ND	ND	0	41.953	0	

463 * average gc/L per sample

464 ND: non detected

465